Jump to content
Forum All Steroids

1 mois d'ALBUTEROL


willidian
 Share

Recommended Posts

Ou ça ??

en voila plusieurs

Br J Sports Med. 2007 May 17; [Epub ahead of print]

Salbutamol exhibits androgenic activity in vitro.

von Bueren AO, Ma R, Schlumpf M, Lichtensteiger W.

Institute of Pharmacology and Toxicology, University of Zurich, Switzerland, Switzerland.

ABSTRACT: Salbutamol has been shown to mediate anabolic effects after intravenous administration. However, the underlying mechanism responsible for anabolic actions of salbutamol remains unknown. OBJECTIVE: To investigate potential mechanism by which salbutamol mediates anabolic effects in vitro. METHODS: Potential androgenic activity of salbutamol was investigated in vitro by the A-Screen assay that measures androgen-dependent inhibition of proliferation of the androgen receptor (AR)-positive human mammary carcinoma cell line, MCF7-AR1. RESULTS: The assay was validated with three known androgens (methyltrienolone (R1881), 5-alphadihydrotestosterone (DHT) and danazol). IC50 values of R1881, DHT and danazol, 4.41 x 10(-11), 4.44 x 10(-11) and 1.08 x 10(-8) M, were in the range known from earlier studies. Our results indicate thatsalbutamol exhibits androgenic activity, with an IC50 value of 8.93 x 10(-6) M. Anti-estrogenic or cytotoxic effects which might have interfered with the assay, were excluded by additional experiments on wildtype MCF7 and MCF7-AR1 cells, respectively. CONCLUSION: These data indicate that salbutamol exerts anabolic effects through androgen receptor agonistic activity in vitro.

PMID: 17510230 [PubMed - as supplied by publisher]

J Strength Cond Res. 2005 Feb;19(1):102-7.Related Articles, Links

Oral albuterol dosing during the latter stages of a resistance exercise program.

Caruso JF, Hamill JL, De Garmo N.

Healthcare Research Associates Inc., Orlando, Florida 32819, USA. john-caruso@utulsa.edu

Subjects performed isoload variable resistance exercise (REX) 3 days per week. After 10 weeks, they received a double-blind albuterol (n = 11) or placebo (n = 11) capsule assignment with no crossover and continued training. During the first week of capsule administration, dosages were increased from 4 mg to 16 mg daily and then maintained for 14 days. At weeks 0, 10, and 13, we measured upper arm and thigh cross-sectional area, knee and elbow extensor and flexor (KE, KF, EE, EF) strength at 3 angular velocities, and lean body mass. Data after 10 weeks showed insignificant between-group differences. From weeks 10-13, as subjects continued REX training, albuterol evoked higher (p < 0.05) KE-KF strength gains at multiple velocities versus placebo dosing. A higher lean body mass trend also occurred with albuterol from weeks 10-13. Results suggest that albuterol augments REX to provide greater strength gains from hypertrophic factors than an REX-placebo assignment.

Publication Types:

Clinical Trial

PMID: 15705021 [PubMed - indexed for MEDLINE]

Aviat Space Environ Med. 2004 Jun;75(6):505-11

Albuterol helps resistance exercise attenuate unloading-induced knee extensor losses.

Caruso JF, Hamill JL, Yamauchi M, Mercado DR, Cook TD, Keller CP, Montgomery AG, Elias J.

Exercise Physiology Laboratory, University of Nevada, Reno, NV, USA. john-caruso@utulsa.edu

INTRODUCTION: While resistance exercise (REX) attenuates knee extensor (KE) mass and strength deficits during short-term unloading, additional treatments concurrently administered with REX are required to reduce the greater losses seen with longer periods of unloading. METHODS: To determine whether Albuterol helps REX attenuate unloading-induced KE losses, two groups of subjects strength trained their left thigh three times per week, and otherwise refrained from ambulatory and weight-bearing activity for 40 d while receiving a capsule dosing treatment (Albuterol, placebo) with no crossover. A third group served as unloaded controls (CTRL). On days 0, 20, and 40, the following data were collected from the nonweight-bearing (left) thigh: cross-sectional area (CSA); integrated electromyography (IEMG); and concentric and eccentric KE strength measures. Thigh CSA was estimated using anthropometric methodology. IEMG was used to provide root mean square (RMS) values from submaximal (100 nm) and maximal isometric contractions. Concentric and eccentric strength were measured from eight-repetition unilateral leg press sets. RESULTS: Repeated-measures mixed-factorial 3 x 3 ANCOVAs with day 0 values as a covariate showed group by time interactions for concentric and eccentric total work (CTW, ETW). Tukey's post hoc test showed REX-Albuterol evoked significant (p < 0.05) day 40 CTW and ETW gains vs. within-group day 0 and within-time REX-placebo and CTRL values. By days 20 and 40, CTRL subjects incurred significant decrements. CONCLUSIONS: Albuterolaugmented the effects of REX to increase CTW and ETW. Research identifying possible mechanisms responsible for such changes, as well as the safety of REX-Albuterol administration in other models, is warranted.

Neurology. 2008 Jan 8;70(2):137-43. Epub 2007 Oct 17.

Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy.

Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ.

David Geffen School of Medicine at UCLA, 635 Charles Young Drive South, NRB1 Room 401, Los Angeles, CA 90095-7334, USA.

BACKGROUND: Albuterol is a beta-2 agonist that has been demonstrated to increase muscle strength in studies in animals and humans. Based on a pilot study of extended-release albuterol Repetabs in children with dystrophinopathies, the authors conducted a randomized, double-blind, placebo-controlled study with a crossover design. METHODS: Fourteen boys with Duchenne or Becker muscular dystrophy, 6 to 11 years old, completed two treatment periods (albuterol and placebo), 12 weeks each, separated by a 12-week washout period. As the albuterol Repetab formulation was no longer available, an alternateextended release albuterol was used (Volmax, 12 mg per day). Outcome measurements included 1) lean body mass, 2) fat mass, 3) isometric knee extensor and flexor moments, 4) manual muscle testing, and 5) timed functional tests. RESULTS: Lean body mass was significantly higher for subjects following albuterol treatment compared to placebo treatment, while fat mass was significantly lower. No differences were found in isometric knee moments or manual muscle tests. Time to run/walk 30 feet was improved following albuterol. CONCLUSIONS: Short-term treatment with extended release albuterol may increase lean body mass, decrease fat mass, and improve functional measures in patients with dystrophinopathies. However, the significant change in strength of specific muscle groups found in the pilot study was not observed in the present study. These findings may be attributed to differences in the drug release and kinetics between Repetab and Volmax formulations as they affect the concentration of available beta-2 receptors on the muscle cell surface differently.

Link to comment
Share on other sites

Background/Objectives: Animal and human studies suggest that b2-adrenergic agonists exert anabolic effects on muscles, inducing and preventing atrophy after a variety of insults. Based on data from an open-label trial of albuterol in 15 patients with facioscapulohumeral dystrophy (FSHD), the authors conducted a randomized, double-blind, placebo-controlled trial of sustained-release albuterol in this disease.Methods: Ninety patients were randomized to three groups: placebo; 8.0 mg albuterol twice daily; or 16.0 mg albuterol twice daily. Patients were treated for 1 year with assessments at baseline and weeks 13, 26, and 52. The primary outcome was the 52-week change in global strength by maximum voluntary isometric contraction testing (MVICT). Secondary outcomes included changes at 52 weeks in strength by manual muscle testing (MMT), grip strength, functional testing, and muscle mass assessed by dual energy x-ray absorptiometry (DEXA).Results: Eighty-four patients completed the study. The mean changes in composite MVICT scores were not significantly different between the groups (mean ± SD: placebo 0.20 ± 0.91; low dose −0.04 ± 0.84; high dose 0.08 ± 0.98). Similarly, there were no differences in the mean MMT change (placebo 0.04 ± 0.16; low dose −0.03 ± 0.13; high dose 0.00 ± 0.15). Grip improved in both treatment groups compared to placebo (placebo −0.53 ± 4.13, low dose +1.90 ± 3.34 [p = 0.02], high dose +1.70 ± 4.13 [p = 0.03]). The high-dose group had a significant increase in lean mass by DEXA (+1.57 ± 1.71 kg) compared to placebo (0.25 ± 2.24; p = 0.007). Albuterol was well tolerated; side effects included cramps, tremors, insomnia, and nervousness.Conclusions: Although albuterol did not improve global strength or function in patients with FSHD, it did increase muscle mass and improve some measures of strength.

Link to comment
Share on other sites

l'ECA n'est pas une cafeine amelioré!!

elle aumgente la temperature du corps, donc logique que tu brule plus de calorie

j'ai bcp d'ami culturo qu'il l'utilise en seche avant des concours avec de tres bon resulat, plutot que de prendre du clembu bien trop dangereux, mais comme d'hab sur ce forum, on dirais que tout le monde a besoin de s'envoyer les dose de mr.Olyumpia pour sentir quelque chose !

Link to comment
Share on other sites

Je viens de finir ma deuxieme semaine à 16 mg/jour

Pas de tremblements ni de crampes,rien du tout.

Par contre une forme terrible,d'habitude quand je fais mes seances après ma journée de boulot je suis un peu fatigué c'est dur parfois.

Mais alors la aucune baisse de regime pendant la seance!!

Link to comment
Share on other sites

Je viens de finir ma deuxieme semaine à 16 mg/jour

Pas de tremblements ni de crampes,rien du tout.

Par contre une forme terrible,d'habitude quand je fais mes seances après ma journée de boulot je suis un peu fatigué c'est dur parfois.

Mais alors la aucune baisse de regime pendant la seance!!

Tu le prend combien de temps avant ta séance?

tu sent l'effet cb de temps?

Tu perd pas de muscle ça va?

Merci

Link to comment
Share on other sites

  • 3 weeks later...

sa m'interesse aussi,pour une femme,j'avais pensé sur 3 semaine a :

jours 1 a 5 : 4 mg

jour 6 a :12 8 mg

jours 13 a 21: 12 mg

vous en pensez quoi ceux qui conaissent et ont testé ?

pour un mec je pensais a

semaine 1 8 mg

semaine 2 et 3 16 mg

mais peut etre que je monte pas assez haut et ne redescend pas assez graduellement ?

Link to comment
Share on other sites

tu fait une diet PDM (prise de masse ) si j'ai bien comprit ? et tu arrive quand même a séché? même si c'est légerement ??

J'espere ... Enfin prise de masse... Pas mal manger autour des training et la crea en plus :)

Oui je pense que je vais secher la :))

Link to comment
Share on other sites

c'est surtout pour eviter les crampes et trop d'effet secondaire que je comptais demarrer bas,monter un peu puis redescendre un peu,je demande surtout a ceux qui conaissent,qui ont testé aussi !

Oui je pense que c'est une bonne chose d'y aller progressivement ...

Plus pour s'habituer au produit, les crampes tu en aura pas si tu prend du magnésium et taurine..

Même en commençant a 16mg direct

Link to comment
Share on other sites

 Share

×
×
  • Create New...